0001178913-18-001598.txt : 20180510
0001178913-18-001598.hdr.sgml : 20180510
20180510173056
ACCESSION NUMBER: 0001178913-18-001598
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180508
FILED AS OF DATE: 20180510
DATE AS OF CHANGE: 20180510
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Domzalski David
CENTRAL INDEX KEY: 0001727794
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36621
FILM NUMBER: 18824210
MAIL ADDRESS:
STREET 1: C/O FOAMIX PHARMACEUTICALS LTD.
STREET 2: 2 HOLZMAN STREET, WEIZMANN SCIENCE PARK
CITY: REHOVOT
STATE: L3
ZIP: 76704
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Foamix Pharmaceuticals Ltd.
CENTRAL INDEX KEY: 0001606645
STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833]
IRS NUMBER: 000000000
STATE OF INCORPORATION: L3
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2 HOLZMAN ST.
STREET 2: WEIZMANN SCIENCE PARK
CITY: REHOVOT
STATE: L3
ZIP: 76704
BUSINESS PHONE: 97289316233
MAIL ADDRESS:
STREET 1: 2 HOLZMAN ST.
STREET 2: WEIZMANN SCIENCE PARK
CITY: REHOVOT
STATE: L3
ZIP: 76704
FORMER COMPANY:
FORMER CONFORMED NAME: Foamix Ltd.
DATE OF NAME CHANGE: 20140428
4
1
zk1821661.xml
OWNERSHIP DOCUMENT
X0306
4
2018-05-08
0
0001606645
Foamix Pharmaceuticals Ltd.
FOMX
0001727794
Domzalski David
C/O FOAMIX PHARMACEUTICALS LTD.
2 HOLZMAN STREET, WEIZMANN SCIENCE PARK
REHOVOT
L3
76704
ISRAEL
1
1
0
0
CEO
Ordinary Shares
2018-05-08
4
A
0
23396
0.00
D
163150
D
Options
5.06
2018-05-08
4
A
0
70187
0
A
2028-02-27
Ordinary Shares
70187
70187
D
The equity incentive grants were approved by the Issuer's board of directors on the recommendation of a committee of the board on February 27, 2019, subject to shareholder approval as required under the Israeli Companies Law. The Issuer's shareholders approved the equity incentive grants on May 8, 2018.
The ordinary shares underlying this restricted share unit award vest over a period of four years (25% on February 27, 2019 and 6.25% every three months thereafter) ending February 27, 2022.
This security represents restricted share units. Each restricted share unit represents a contingent right to receive one ordinary share of the issuer.
Each option represents a contingent right to purchase one ordinary share of the issuer.
The ordinary shares underlying these options vest over a period of four years (25% on February 27, 2019 and 6.25% every three months thereafter) ending February 27, 2022.
/s/ Ilan Hadar as attorney-in-fact for David Domzalski
2018-05-10